2nd Quarter - Report — GENENTECH, INC for GENENTECH INC (2008)

Firm

GENENTECH, INC

Client

GENENTECH INC

Income

—

Expenses

$562,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 5480, Medicare Funding Warning Response Act of 2008 S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 Comparative Effectiveness H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008 S. 3101, Medicare Improvements for Patients and Providers Act of 2008

Lobbyist	Covered position, as disclosed
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Bills named: S. 3101 (110th), H.R. 6331 (110th), S. 2662 (110th), S. 2029 (110th), H.R. 5480 (110th)

Budget/Appropriations BUD

House Concurrent Resolution 312 FY09 Budget Resolution Senate Concurrent Resolution 70 FY09 budget Resolution Comparative Effectiveness

Lobbyist	Covered position, as disclosed
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Pharmacy PHA

H.R. 1038, Acces to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act H.R. 4911, Human Growth Hormone Restriction Act of 2007 H.R. 5839, Safeguarding America's Pharmaceuticals Act S. 1505 Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics S. 877, Controlling Abuse of Prescription Drugs Act of 2007

Lobbyist	Covered position, as disclosed
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2029 (110th), S. 623 (110th), H.R. 5839 (110th), S. 1695 (110th), S. 596 (110th), H.R. 1956 (110th), S. 877 (110th), H.R. 4911 (110th), H.R. 5629 (110th), H.R. 1038 (110th), S. 1505 (110th)

Medical/Disease Research/Clinical Labs MED

LHHS Appropriations (CMS and comparative effectiveness related matters)

Lobbyist	Covered position, as disclosed
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.